It has been revealed that the CCL2‐CCR2 signalling axis participated in the occurrence and progression of a wide range of malignancies, such as breast cancer,44 prostate cancer,45 lung cancer,46 hepatocellular cancer,47 pancreatic cancer,48 nasopharyngeal carcinoma49 and renal cancer.50 This evidence concerns the gene CCL2 and breast cancer.